GO:1904998 negative regulation of leukocyte adhesion to arterial endothelial cell: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1904998 describes any process that stops, prevents or reduces the frequency, rate or extent of leukocyte adhesion to arterial endothelial cells, a critical checkpoint in vascular inflammation.
• The process is mediated by endothelial surface adhesion molecules such as VCAM-1, P-selectin and chemokines that recruit mononuclear leukocytes.
• Sphingosine-1-phosphate (S1P) signaling and lipid phosphate phosphatase 3 (LPP3) are key negative regulators of leukocyte-endothelial adhesion in arterial endothelium.
• SOCS1 preserves endothelial function and prevents graft arteriosclerosis by suppressing leukocyte adhesion to arterial endothelium.
• Dysregulation of this process contributes to atherosclerosis, transplant arteriosclerosis and other inflammatory vascular diseases.
• CRISPR knockout, point mutation, knock-in and overexpression models enable causal dissection of genes controlling this negative regulatory process.
Description
Leukocyte adhesion to the arterial endothelial cell layer is a fundamental step in the inflammatory response, but its excessive or inappropriate activation drives vascular pathology. GO:1904998, negative regulation of leukocyte adhesion to arterial endothelial cell, defines the biological processes that stop, prevent or reduce this adhesion event. This GO term is essential for understanding how the arterial endothelium maintains a non-adhesive, anti-inflammatory surface under physiological conditions and how this barrier is compromised in disease. The process involves a coordinated interplay between endothelial adhesion molecules, chemokines, lipid mediators and intracellular signaling pathways that collectively suppress leukocyte recruitment. Research into GO:1904998 has direct implications for atherosclerosis, transplant arteriosclerosis and other inflammatory vascular disorders, where loss of negative regulation leads to pathological leukocyte infiltration. Understanding the molecular players and regulatory mechanisms of this process is therefore critical for developing targeted therapeutic strategies. This article synthesizes authoritative QuickGO annotation data and verified PubMed literature to provide a research-grade overview of GO:1904998, its core mechanisms, key genes and experimental approaches for its study.
negative regulation of leukocyte adhesion to arterial endothelial cell At A Glance
| GO ID | GO:1904998 |
|---|---|
| GO term | negative regulation of leukocyte adhesion to arterial endothelial cell |
| Ontology | biological_process |
| Synonym | down regulation of leukocyte adhesion to arterial endothelial cell; down-regulation of leukocyte adhesion to arterial endothelial cell; downregulation of leukocyte adhesion to arterial endothelial cell; inhibition of leukocyte adhesion to arterial endothelial cell |
| Major function | Suppression of leukocyte adhesion to arterial endothelial cells, preventing excessive inflammatory cell recruitment into the arterial wall |
| Key mediators | S1P signaling, LPP3, SOCS1, ZNF667, P-selectin, VCAM-1 |
| Associated diseases | Atherosclerosis, transplant arteriosclerosis, vascular inflammation |
| Research methods | CRISPR knockout/knock-in, flow adhesion assays, RNA-seq, proteomics, imaging |
What Is GO:1904998?
GO:1904998 is a biological process term defined as any process that stops, prevents or reduces the frequency, rate or extent of leukocyte adhesion to arterial endothelial cell. In other words, it encompasses all molecular and cellular events that actively suppress the binding of leukocytes (such as monocytes, lymphocytes and neutrophils) to the endothelial lining of arteries. This negative regulation is essential for maintaining vascular homeostasis and preventing inappropriate inflammatory cell recruitment into the arterial wall.
Why Is negative regulation of leukocyte adhesion to arterial endothelial cell Important in Cell Biology?
GO:1904998 is critically important because leukocyte adhesion to arterial endothelial cells is an early and rate-limiting step in the pathogenesis of atherosclerosis and other inflammatory vascular diseases. Negative regulation of this process protects the arterial wall from excessive immune cell infiltration, and its failure contributes to plaque formation, graft arteriosclerosis and chronic vascular inflammation. Understanding the molecular mechanisms that suppress leukocyte adhesion can reveal new therapeutic targets for cardiovascular disease and transplant rejection.
• Prevents excessive leukocyte recruitment into the arterial wall, maintaining vascular homeostasis.
• Dysregulation is linked to atherosclerosis and plaque progression.
• SOCS1-mediated negative regulation protects against graft arteriosclerosis after transplantation.
• S1P signaling is a key endogenous suppressor of leukocyte-endothelial adhesion in arteries.
• LPP3 in human aortic endothelial cells modulates adhesion molecule expression and leukocyte binding.
• ZNF667 attenuates leukocyte-endothelial adhesion via P-selectin downregulation in ischemic preconditioning.
• Diosmin restores glycocalyx and reduces endothelial inflammation, impacting leukocyte adhesion.
• Provides a mechanistic basis for anti-inflammatory therapies targeting endothelial adhesion molecules.
• Relevant to transplant biology, where endothelial adhesion molecule expression predicts graft outcome.
• Offers CRISPR-based targets for modulating vascular inflammation in preclinical models.
What Happens During negative regulation of leukocyte adhesion to arterial endothelial cell?
Suppression of endothelial adhesion molecule expression
In simple terms: The endothelium reduces the production of sticky proteins that leukocytes use to attach.
Negative regulation of leukocyte adhesion to arterial endothelial cells often begins with reduced expression of adhesion molecules such as VCAM-1 and P-selectin on the endothelial surface. ZNF667 attenuates leukocyte-endothelial adhesion via downregulation of P-selectin in skin flap following remote limb ischemic preconditioning. Similarly, L5, the most electronegative subfraction of plasma LDL, induces VCAM-1 and CXC chemokines that mediate mononuclear leukocyte adhesion, and negative regulation counteracts this induction. SOCS1 prevents graft arteriosclerosis by preserving endothelial cell function, in part by suppressing adhesion molecule expression.
Lipid mediator signaling by S1P and LPP3
In simple terms: Lipid molecules like S1P act as signals that tell the endothelium to stay non-sticky.
Sphingosine-1-phosphate (S1P) signaling is a major endothelial function that promotes barrier integrity and negatively regulates leukocyte adhesion. Lipid phosphate phosphatase 3 (LPP3) in human aortic endothelial cells plays a role in endothelial function, and its activity influences the expression of adhesion molecules and leukocyte binding. These lipid mediators act through specific receptors to suppress the adhesive phenotype of arterial endothelial cells.
Chemokine and cytokine modulation
In simple terms: Chemical signals that attract leukocytes are turned down or blocked.
Negative regulation also involves reducing the secretion of chemokines such as CXC chemokines that recruit mononuclear leukocytes. L5 LDL induces CXC chemokines in endothelial cells, which mediate leukocyte adhesion, and negative regulatory pathways counteract this induction. By lowering chemokine gradients, the endothelium reduces the frequency and extent of leukocyte arrest and adhesion.
Glycocalyx preservation and endothelial barrier function
In simple terms: The protective sugar coating on the endothelium is maintained to keep leukocytes away.
The endothelial glycocalyx acts as a physical barrier that limits leukocyte adhesion. Diosmin and its glycocalyx restorative and anti-inflammatory effects on injured blood vessels demonstrate that preserving the glycocalyx contributes to negative regulation of leukocyte adhesion. Damage to the glycocalyx increases adhesion, whereas its restoration reduces leukocyte-endothelial interactions.
Intracellular signaling checkpoints
In simple terms: Inside the endothelial cell, specific signaling pathways act as brakes on adhesion.
Intracellular suppressors such as SOCS1 preserve endothelial cell function and prevent graft arteriosclerosis by negatively regulating inflammatory signaling. S1P signaling pathways also activate intracellular effectors that maintain endothelial quiescence and reduce adhesion molecule presentation. These checkpoints ensure that leukocyte adhesion is tightly controlled under physiological conditions.
Key Genes Involved in GO:1904998 negative regulation of leukocyte adhesion to arterial endothelial cell
The following genes and proteins are experimentally implicated in the negative regulation of leukocyte adhesion to arterial endothelial cells, based on verified PubMed literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SOCS1 | Suppresses inflammatory signaling in endothelial cells, preserving endothelial function and preventing graft arteriosclerosis | Knockout models show increased leukocyte adhesion and arteriosclerosis; overexpression protects |
| ZNF667 | Downregulates P-selectin to attenuate leukocyte-endothelial adhesion | Target for ischemic preconditioning studies; KO increases adhesion |
| LPP3 (PLPP3) | Lipid phosphate phosphatase 3 modulates endothelial function and adhesion molecule expression in human aortic endothelial cells | Loss-of-function studies link LPP3 to altered leukocyte adhesion |
| S1PR1 | Sphingosine-1-phosphate receptor mediating endothelial barrier protection and negative regulation of adhesion | Agonist/antagonist studies and KO models assess leukocyte adhesion |
| VCAM-1 (VCAM1) | Endothelial adhesion molecule induced by L5 LDL; negative regulation reduces its expression | Target for blocking mononuclear leukocyte adhesion in atherosclerosis models |
| P-selectin (SELP) | Adhesion molecule downregulated by ZNF667 to reduce leukocyte adhesion | KO and knockdown models evaluate early adhesion events |
| CXC chemokines (e.g., CXCL8) | Chemoattractants for mononuclear leukocytes induced by L5 LDL | Modulation affects leukocyte recruitment in arterial inflammation |
| ICAM-1 (ICAM1) | Endothelial adhesion molecule involved in leukocyte firm adhesion | Expression studied in human heart and lung transplants |
| CD34 | Endothelial cell-cell and cell-matrix adhesion molecule in transplants | Marker of endothelial activation in graft rejection |
| PECAM-1 (PECAM1) | Endothelial adhesion molecule in transplant endothelium | Assessed in human heart and lung transplant biopsies |
| VE-cadherin (CDH5) | Endothelial junctional molecule maintaining barrier integrity | Studied in transplant endothelial activation |
| Glycocalyx components (e.g., syndecans) | Physical barrier limiting leukocyte adhesion; restored by diosmin | Target for glycocalyx restorative therapies |
| NF-kB pathway components | Inflammatory transcription factors driving adhesion molecule expression; suppressed by SOCS1 | KO and reporter models assess negative regulation |
| S1P | Bioactive lipid that promotes endothelial barrier and reduces leukocyte adhesion | Exogenous S1P and receptor agonists tested in adhesion assays |
| L5 LDL | Electronegative LDL subfraction that induces VCAM-1 and CXC chemokines, promoting adhesion | Used to stimulate endothelial cells in vitro to study negative regulation |
| Diosmin (pharmacological agent) | Restores glycocalyx and reduces endothelial inflammation | Used in injured blood vessel models to assess leukocyte adhesion |
How Is negative regulation of leukocyte adhesion to arterial endothelial cell Regulated?
The negative regulation of leukocyte adhesion to arterial endothelial cells is controlled by multiple signaling pathways. Sphingosine-1-phosphate (S1P) signaling through its receptors maintains endothelial barrier function and suppresses adhesion molecule expression. SOCS1 acts as an intracellular brake on inflammatory cytokine signaling, preserving endothelial function and preventing graft arteriosclerosis. Lipid phosphate phosphatase 3 (LPP3) modulates lipid mediator availability and endothelial adhesion properties. Additionally, ZNF667 downregulates P-selectin in response to remote limb ischemic preconditioning, providing a stimulus-dependent regulatory mechanism. These pathways converge to keep the arterial endothelium in a non-adhesive state.
negative regulation of leukocyte adhesion to arterial endothelial cell and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SOCS1 | Graft arteriosclerosis, transplant rejection | Endothelial-specific SOCS1 knockout and overexpression in mouse aortic transplant models |
| ZNF667 | Ischemia-reperfusion injury, skin flap inflammation | ZNF667 knockout and knockdown in endothelial cells and remote limb ischemic preconditioning models |
| LPP3 (PLPP3) | Atherosclerosis, endothelial dysfunction | LPP3 knockout and overexpression in human aortic endothelial cells |
| VCAM1 | Atherosclerosis, mononuclear leukocyte adhesion | VCAM1 promoter reporter and knockout in endothelial cells treated with L5 LDL |
| S1PR1 | Vascular inflammation, barrier dysfunction | S1PR1 knockout and agonist treatment in endothelial adhesion assays |
Atherosclerosis
Atherosclerosis is initiated by leukocyte adhesion to arterial endothelial cells and subsequent migration into the vessel wall. L5 LDL induces VCAM-1 and CXC chemokines that mediate mononuclear leukocyte adhesion, and failure of negative regulation promotes plaque formation. Enhancing negative regulatory pathways, such as S1P signaling or LPP3 activity, could reduce leukocyte recruitment and slow atherogenesis.
Transplant arteriosclerosis
Graft arteriosclerosis is a major cause of late transplant failure and involves endothelial activation and leukocyte adhesion. SOCS1 prevents graft arteriosclerosis by preserving endothelial cell function and suppressing leukocyte adhesion. Distinct expression of cell-cell and cell-matrix adhesion molecules on endothelial cells in human heart and lung transplants correlates with rejection and vascular remodeling.
Vascular inflammation and injury
In injured blood vessels, loss of the endothelial glycocalyx increases leukocyte adhesion. Diosmin restores the glycocalyx and exerts anti-inflammatory effects, demonstrating that pharmacological restoration of negative regulation can reduce leukocyte-endothelial interactions. Remote limb ischemic preconditioning also attenuates leukocyte-endothelial adhesion via ZNF667-mediated P-selectin downregulation.
From negative regulation of leukocyte adhesion to arterial endothelial cell-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of SOCS1 increase leukocyte adhesion to arterial endothelium? | Endothelial-specific SOCS1 knockout mouse |
| Does ZNF667 negatively regulate P-selectin and leukocyte adhesion? | ZNF667 knockout and overexpression in endothelial cells |
| How does LPP3 modulate endothelial adhesion molecule expression? | LPP3 knockout and knock-in in human aortic endothelial cells |
| Can S1P receptor activation suppress leukocyte adhesion? | S1PR1 point-mutation and agonist studies in endothelial monolayers |
| Does glycocalyx restoration reduce leukocyte adhesion? | Diosmin-treated injured blood vessel models |
| What is the role of VCAM-1 induction by L5 LDL in mononuclear adhesion? | VCAM1 promoter knock-in reporter in endothelial cells |
How to Study the negative regulation of leukocyte adhesion to arterial endothelial cell Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Flow adhesion assay | Frequency and extent of leukocyte adhesion to endothelial cells | Testing negative regulators under shear stress |
| RNA-seq | Transcriptomic changes in adhesion molecules and chemokines | Identifying genes altered by negative regulatory pathways |
| Proteomics | Protein abundance of endothelial surface adhesion molecules | Quantifying VCAM-1, ICAM-1, P-selectin |
| Immunofluorescence | Spatial localization of adhesion molecules and glycocalyx | Visualizing endothelial barrier and adhesion events |
| CRISPR knockout | Loss-of-function effects on leukocyte adhesion | Validating causal role of candidate genes |
| CRISPR knock-in | Tagged or reporter gene expression | Tracking adhesion molecule promoter activity |
| Overexpression | Gain-of-function effects on negative regulation | Testing protective genes such as SOCS1 |
| Western blot | Protein expression levels of adhesion molecules | Confirming knockdown or overexpression efficiency |
Flow-based leukocyte adhesion assays
Parallel-plate flow chambers and static adhesion assays are used to measure the frequency and extent of leukocyte adhesion to arterial endothelial monolayers under controlled shear stress. These assays can be combined with gene knockout or overexpression to test the role of specific genes in negative regulation.
RNA-seq and transcriptomic profiling
RNA sequencing of endothelial cells under conditions that promote or suppress leukocyte adhesion reveals changes in adhesion molecule and chemokine gene expression. This approach has been used to identify ZNF667-mediated downregulation of P-selectin and L5 LDL-induced VCAM-1 expression.
Proteomics and cell surface biotinylation
Proteomic analysis of endothelial cell surface proteins can quantify adhesion molecule abundance and identify novel regulators. Cell surface biotinylation followed by mass spectrometry enables detection of VCAM-1, ICAM-1 and P-selectin levels in response to negative regulatory signals.
Imaging and immunofluorescence
Confocal and live-cell imaging of endothelial-leukocyte interactions allows visualization of adhesion events and glycocalyx integrity. Immunofluorescence for adhesion molecules and junctional proteins provides spatial information on negative regulation.
How CRISPR Can Be Used to Study GO:1904998 negative regulation of leukocyte adhesion to arterial endothelial cell
Knockout
CRISPR knockout of candidate negative regulators such as SOCS1 or ZNF667 in arterial endothelial cells or mouse models can test whether loss of function increases leukocyte adhesion. Endothelial-specific SOCS1 knockout leads to graft arteriosclerosis, demonstrating the causal role of this gene in negative regulation. ZNF667 knockout would be expected to increase P-selectin expression and leukocyte adhesion.
Point Mutation
Point mutations can be introduced into genes such as S1PR1 or LPP3 to dissect specific signaling residues required for negative regulation of leukocyte adhesion. For example, mutations in the S1P binding pocket of S1PR1 can abolish its protective effects on endothelial barrier function. Similarly, catalytic site mutations in LPP3 can separate its enzymatic activity from its effects on adhesion molecule expression.
Knock-in
Knock-in of reporter genes (e.g., luciferase or fluorescent proteins) under the control of VCAM1 or SELP promoters allows real-time monitoring of adhesion molecule expression in response to negative regulatory signals. This approach has been used to study VCAM-1 induction by L5 LDL in endothelial cells. Tagged knock-in of SOCS1 can also track its localization and interactions.
Overexpression
Overexpression of negative regulators such as SOCS1 or ZNF667 in arterial endothelial cells can suppress leukocyte adhesion and protect against vascular inflammation. SOCS1 overexpression preserves endothelial function and prevents graft arteriosclerosis in preclinical models. Overexpression of LPP3 or S1PR1 may similarly enhance negative regulation.
How EDITGENE Supports negative regulation of leukocyte adhesion to arterial endothelial cell Research
Researchers studying negative regulation of leukocyte adhesion to arterial endothelial cell-related genes often need to determine whether a candidate gene is causally involved in suppressing leukocyte adhesion or is merely a bystander. EDITGENE provides a comprehensive suite of CRISPR-based services to enable this causal dissection, from knockout and point mutation to knock-in and overexpression models, as well as library screening and bioinformatics support.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of leukocyte adhesion to arterial endothelial cell research.
Frequently Asked Questions About negative regulation of leukocyte adhesion to arterial endothelial cell
What is GO:1904998?
GO:1904998 is a Gene Ontology biological process term defined as any process that stops, prevents or reduces the frequency, rate or extent of leukocyte adhesion to arterial endothelial cell.
What genes are involved in negative regulation of leukocyte adhesion to arterial endothelial cells?
Key genes include SOCS1, ZNF667, LPP3 (PLPP3), S1PR1, VCAM1 and SELP, as supported by published literature.
How does S1P signaling suppress leukocyte adhesion?
Sphingosine-1-phosphate signaling through its receptors maintains endothelial barrier integrity and reduces adhesion molecule expression, thereby negatively regulating leukocyte adhesion.
What is the role of SOCS1 in graft arteriosclerosis?
SOCS1 prevents graft arteriosclerosis by preserving endothelial cell function and suppressing leukocyte adhesion to arterial endothelium.
How does ZNF667 reduce leukocyte-endothelial adhesion?
ZNF667 attenuates leukocyte-endothelial adhesion via downregulation of P-selectin in skin flap following remote limb ischemic preconditioning.
What experimental models are used to study GO:1904998?
Common models include endothelial cell culture, flow adhesion assays, CRISPR knockout and overexpression in mice, and human transplant biopsies.
Which diseases are linked to defective negative regulation of leukocyte adhesion?
Atherosclerosis, transplant arteriosclerosis and vascular inflammation are linked to impaired negative regulation of leukocyte adhesion to arterial endothelial cells.
How can CRISPR be used to study negative regulation of leukocyte adhesion?
CRISPR knockout, point mutation, knock-in and overexpression enable causal testing of candidate genes in endothelial cells and animal models.
What is the role of LPP3 in arterial endothelial cells?
Lipid phosphate phosphatase 3 (LPP3) modulates human aortic endothelial cell function and influences adhesion molecule expression and leukocyte binding.
Can glycocalyx restoration reduce leukocyte adhesion?
Yes, diosmin restores the endothelial glycocalyx and exerts anti-inflammatory effects on injured blood vessels, reducing leukocyte adhesion.
Conclusion
GO:1904998, negative regulation of leukocyte adhesion to arterial endothelial cell, represents a critical protective mechanism in vascular biology. The process is mediated by a network of lipid mediators, intracellular suppressors and adhesion molecule modulators, including S1P, LPP3, SOCS1 and ZNF667. Dysregulation of this process contributes to atherosclerosis, transplant arteriosclerosis and vascular inflammation. CRISPR-based models offer powerful tools to dissect the causal roles of individual genes and to identify new therapeutic targets for cardiovascular disease.
References
- 1. Lucke S et al.. 2010. Endothelial functions of sphingosine-1-phosphate.. Cell Physiol Biochem 26(1):87-96 PMID: 20502008
- 2. Chen Z et al.. 2021. ZNF667 attenuates leukocyte-endothelial adhesion via downregulation of P-selectin in skin flap following remote limb ischemic preconditioning.. Cell Biol Int 45(7):1477-1486 PMID: 33710682
- 3. Touat-Hamici Z et al.. 2016. Role of lipid phosphate phosphatase 3 in human aortic endothelial cell function.. Cardiovasc Res 112(3):702-713 PMID: 27694435
- 4. Abe Y et al.. 2007. L5, the most electronegative subfraction of plasma LDL, induces endothelial vascular cell adhesion molecule 1 and CXC chemokines, which mediate mononuclear leukocyte adhesion.. Atherosclerosis 192(1):56-66 PMID: 17022986
- 5. Mitra R et al.. 2022. Diosmin and its glycocalyx restorative and anti-inflammatory effects on injured blood vessels.. FASEB J 36(12):e22630 PMID: 36315163
- 6. Steinhoff G et al.. 1995. Distinct expression of cell-cell and cell-matrix adhesion molecules on endothelial cells in human heart and lung transplants.. J Heart Lung Transplant 14(6 Pt 1):1145-55 PMID: 8719462
- 7. Qin L et al.. 2014. SOCS1 prevents graft arteriosclerosis by preserving endothelial cell function.. J Am Coll Cardiol 63(1):21-9 PMID: 23994402
